Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered...
7 insider purchases on record · latest filing 2025-12-29.
Insiders have also filed 57 sale transactions at IPSC.